With a distinguished 30-year career as a top financial executive, Caroline Dorsa brings strong financial credentials and management expertise to Intellia’s Board of Directors, which she joined in 2015. In addition to her membership on Intellia’s board, she serves on the boards of directors for Biogen, Inc., where she chairs the audit committees, and Illumina, Inc. She is also on the board of trustees of several Goldman Sachs investment funds, such as the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund and the Goldman Sachs MLP Income Opportunities Fund.
Caroline served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group, an integrated provider of regulated utility electric and gas distribution services, from April 2009 until her retirement in October 2015. Prior to that she served as Senior Vice President, Global Human Health, Strategy and Integration for Merck & Co. and Senior Vice President and CFO at Avaya, Inc., where she oversaw its leveraged buyout in 2007.
Caroline was honored in 2015 with the New Jersey Governor’s Jefferson Award for Public Service for her support of youth development in the state. She holds an MBA from Columbia University and earned her B.A. at Colgate University.
What is Caroline Dorsa's net worth?
The estimated net worth of Caroline Dorsa is at least $104,183.70 as of April 5th, 2021. Ms. Dorsa owns 12,910 shares of Intellia Therapeutics stock worth more than $104,184 as of March 30th. This net worth approximation does not reflect any other assets that Ms. Dorsa may own. Learn More about Caroline Dorsa's net worth.
How do I contact Caroline Dorsa?
The corporate mailing address for Ms. Dorsa and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at lina.li@intelliatx.com. Learn More on Caroline Dorsa's contact information.
Has Caroline Dorsa been buying or selling shares of Intellia Therapeutics?
Caroline Dorsa has not been actively trading shares of Intellia Therapeutics within the last three months. Most recently, Caroline Dorsa sold 7,500 shares of the business's stock in a transaction on Monday, April 5th. The shares were sold at an average price of $82.19, for a transaction totalling $616,425.00. Following the completion of the sale, the director now directly owns 12,910 shares of the company's stock, valued at $1,061,072.90. Learn More on Caroline Dorsa's trading history.
Who are Intellia Therapeutics' active insiders?
Are insiders buying or selling shares of Intellia Therapeutics?
In the last year, insiders at the sold shares 6 times. They sold a total of 31,417 shares worth more than $400,085.72. The most recent insider tranaction occured on January, 29th when Director Muna Bhanji sold 265 shares worth more than $2,642.05. Insiders at Intellia Therapeutics own 3.2% of the company.
Learn More about insider trades at Intellia Therapeutics. Information on this page was last updated on 1/29/2025.
